Natixis Advisors LLC Acquires 35,828 Shares of Sanofi (NASDAQ:SNY)

Natixis Advisors LLC raised its holdings in Sanofi (NASDAQ:SNY) by 1.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,910,021 shares of the company’s stock after acquiring an additional 35,828 shares during the period. Natixis Advisors LLC owned about 0.11% of Sanofi worth $140,350,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Synergy Asset Management LLC acquired a new position in shares of Sanofi in the fourth quarter valued at approximately $25,000. McClarren Financial Advisors Inc. increased its stake in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after buying an additional 543 shares during the period. Sunbelt Securities Inc. increased its position in Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares during the period. Sierra Ocean LLC acquired a new stake in Sanofi during the 4th quarter valued at approximately $44,000. Finally, Versant Capital Management Inc acquired a new stake in Sanofi during the 4th quarter valued at approximately $54,000. Institutional investors own 14.04% of the company’s stock.

Analysts Set New Price Targets

SNY has been the subject of a number of recent analyst reports. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $60.00.

Sanofi Price Performance

Shares of SNY opened at $57.75 on Friday. Sanofi has a 12-month low of $45.22 and a 12-month high of $60.12. The business’s fifty day moving average is $53.65 and its 200 day moving average is $52.86. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The stock has a market cap of $146.56 billion, a P/E ratio of 23.19, a P/E/G ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sell-side analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.